Related Experiment Video
Updated: Aug 9, 2026
10:17
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
Diagnostics for confounding in PK/PD models for oxcarbazepine
Jerry R Nedelman1, Donald B Rubin, Lewis B Sheiner
1Biostatistics and Statistical Reporting, Novartis Pharmaceuticals, East Hanover, NJ 07936, USA. jerry.nedelman@novartis.com
Statistics in Medicine
|April 15, 2006
Summary
This study introduces methods to identify bias in pharmacokinetic/pharmacodynamic (PK/PD) relationships, ensuring accurate drug effect assessments. Diagnostics were developed and applied to oxcarbazepine therapy in adults and children.
Area of Science:
- Pharmacology
- Clinical Trial Design
- Biostatistics
Background:
- Pharmacokinetic/pharmacodynamic (PK/PD) relationships link drug concentration to therapeutic effects.
- Conventional PK/PD assessments in dose-controlled trials may be biased due to confounding.
- True PK/PD relationships are independent of the dose required to achieve target concentrations.
Purpose of the Study:
- To develop and validate diagnostics for confounding in PK/PD relationships.
- To assess PK/PD relationships for oxcarbazepine in adults and children.
- To support the bridging argument for pediatric oxcarbazepine monotherapy approval.
Main Methods:
- Devised statistical diagnostics to detect confounding in PK/PD relationships.
- Applied these diagnostics to clinical trial data of oxcarbazepine adjunctive therapy.
- Compared PK/PD relationships between adult and pediatric populations.
Main Results:
- Demonstrated that conventional PK/PD relationships can be biased estimates of true relationships.
- Developed reliable diagnostics for identifying and quantifying this bias.
- Showed similarity in true PK/PD relationships between adults and children for oxcarbazepine.
Conclusions:
- The developed diagnostics can identify confounding in PK/PD assessments.
- The findings support the use of oxcarbazepine monotherapy in children by bridging from adult data.
- Accurate PK/PD relationship assessment is crucial for effective drug therapy and regulatory decisions.
Related Concept Videos
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:15Pharmacodynamic Models: Linear Concentration–Effect Model
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.